Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL8 alemtuzumab consolidation in chronic lymphocytic leukemia
ISRCTN63375144Phase 3Terminated
- Sponsor
- Leeds Teaching Hospitals NHS Trust
- Start
- Jun 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of alemtuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Leeds Teaching Hospitals NHS Trust. Primary endpoint: Progression-free survival. Started Jun 2008; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ISRCTN63375144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN63375144.